Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Letno srečanje ASCO
Authors:ID Čufer, Tanja (Author)
Files:.pdf PDF - Presentation file, download (1,18 MB)
MD5: DB394AED358E995AD5C6942B5420B414
PID: 20.500.12556/dirros/350c04b1-ea3d-4086-8a08-de974893dc0a
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Keywords:klinična onkologija, imunoterapija, imunska zdravila, novosti
Publication status:Published
Publication version:Version of Record
Year of publishing:2015
Number of pages:str. 30-32
Numbering:Letn. 19, št. 1
PID:20.500.12556/DiRROS-8154 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:2139771 New window
Copyright:by Authors
Publication date in DiRROS:19.03.2018
Views:3701
Downloads:825
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:03.01.2018

Secondary language

Language:English
Title:ASCO Annual Meeting
Abstract:In the end of May this year, Chicago hosted the traditional annual meeting of oncologists from around the world, which was organised by the American Society of Clinical Oncology (ASCO). Once again, the meeting was attended by more than 30,000 oncologists and other scientists from all over the world. The main topic of this year’s ASCO meeting was definitely cancer immunotherapy. For many years, we have hoped to be able to destroy or at least control cancer cells by stimulating the organism’s own defence. There have been some ups but mostly many downs of immunotherapy. Interferons, interleukins and vaccines have shown a very small level of efficacy, and, even so, only in some types of cancer, alongside a disproportionally high toxicity. A breakthrough was achieved a few years ago, when new immuno-medicines, inhibitors of control switches in T lymphocytes (so-called checkpoint inhibitors), were introduced into clinical trials. In many types of cancer, these medicines led to remissions, which were, most importantly, long-term in patients with remission.


Archive

niGradiv

Back